Obesity Clinical Trial
Official title:
Intervening in Food Insecurity to Reduce and Mitigate (InFoRM) Childhood Obesity
Verified date | November 2023 |
Source | Boston Children's Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The goals of this study are to 1) pilot the feasibility of a novel meal kit delivery intervention in families and children with food insecurity and obesity and 2) evaluate the implementation of the pilot intervention.
Status | Completed |
Enrollment | 30 |
Est. completion date | July 21, 2023 |
Est. primary completion date | June 21, 2023 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 6 Years to 12 Years |
Eligibility | Inclusion Criteria: - Children >=6 years and <12 years old with a BMI >=95th percentile - Children who screen positive on the 2-item Hunger Vital Sign™ - Children living in a household of <=5 people - Children living with an English and/or Spanish-speaking caregiver - Children living within the EatWell delivery map boundaries in the greater Boston area Exclusion Criteria: - History of food allergies or intolerance to dairy, gluten, soy, or any potential component of the meal kit - History of malabsorptive intestinal disease (e.g., Crohn's disease, celiac disease) - History of type 1 or 2 diabetes - History of solid tumor or bone marrow transplant - Enteral tube dependence |
Country | Name | City | State |
---|---|---|---|
United States | Boston Children's Hospital | Boston | Massachusetts |
Lead Sponsor | Collaborator |
---|---|
Boston Children's Hospital |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Dietary Assessment: child | The PrimeScreen survey will be used to assess dietary changes for the child (parent-reported). The survey enables calculation of a food group's daily intake frequency. | 0-4 months | |
Other | Dietary Assessment: parent | The PrimeScreen survey will be used to assess dietary changes for the parent (self-reported). | 0-4 months | |
Other | Mealtime Behaviors | Parents will rate Likert scale items from 1 (never) to 5 (everyday) about the frequency of mealtime behaviors and interactions with their child. We will compare these frequencies at baseline, mid-study and completion of study. | 0-4 months | |
Other | Perceived Stress | The Perceived Stress Scale will be used to assess changes in stress (parent self-reported). Scores range from 0 to 40 with higher scores indicating higher perceived stress:
0-13: low stress 14-26: moderate stress 27-40: high perceived stress |
0-4 months | |
Primary | Study Feasibility: Recruitment | Number of participants enrolled per month | 0-4 months | |
Primary | Study Feasibility: Randomization | Proportion of eligible screens who enroll | 0-4 months | |
Primary | Study Feasibility: Retention | Proportion of participants who remain in the study at each study visit | 0-4 months | |
Primary | Study Feasibility: Protocol/Adherence | Treatment-specific fidelity rates, including proportion of meal kits delivered, proportion of meal kits received, proportion of meal kits prepared, and proportion of meal kits consumed | 0-4 months | |
Primary | Study Feasibility: Assessments | Proportion of planned assessments completed at each study visit | 0-4 months | |
Secondary | Household Food Insecurity | Severity of food insecurity will be assessed using the US Household Food Security Survey Module, which is categorized by the raw score into:
Zero: High food security 1-2: Marginal food security 3-7: Low food security 8-18: Very low food security |
0-4 months | |
Secondary | Change in Child BMI | Weight and height will be combined to report BMI in kg/m^2 based on CDC growth curves. | 0-4 months | |
Secondary | Change in Child BMI percent of the 95th percentile | Weight and height will be combined to report BMI in kg/m^2 based on CDC growth curves. | 0-4 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04101669 -
EndoBarrier System Pivotal Trial(Rev E v2)
|
N/A | |
Recruiting |
NCT04243317 -
Feasibility of a Sleep Improvement Intervention for Weight Loss and Its Maintenance in Sleep Impaired Obese Adults
|
N/A | |
Terminated |
NCT03772886 -
Reducing Cesarean Delivery Rate in Obese Patients Using the Peanut Ball
|
N/A | |
Completed |
NCT03640442 -
Modified Ramped Position for Intubation of Obese Females.
|
N/A | |
Completed |
NCT04506996 -
Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management 2
|
N/A | |
Recruiting |
NCT06019832 -
Analysis of Stem and Non-Stem Tibial Component
|
N/A | |
Active, not recruiting |
NCT05891834 -
Study of INV-202 in Patients With Obesity and Metabolic Syndrome
|
Phase 2 | |
Active, not recruiting |
NCT05275959 -
Beijing (Peking)---Myopia and Obesity Comorbidity Intervention (BMOCI)
|
N/A | |
Recruiting |
NCT04575194 -
Study of the Cardiometabolic Effects of Obesity Pharmacotherapy
|
Phase 4 | |
Completed |
NCT04513769 -
Nutritious Eating With Soul at Rare Variety Cafe
|
N/A | |
Withdrawn |
NCT03042897 -
Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer
|
N/A | |
Completed |
NCT03644524 -
Heat Therapy and Cardiometabolic Health in Obese Women
|
N/A | |
Recruiting |
NCT05917873 -
Metabolic Effects of Four-week Lactate-ketone Ester Supplementation
|
N/A | |
Active, not recruiting |
NCT04353258 -
Research Intervention to Support Healthy Eating and Exercise
|
N/A | |
Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
Recruiting |
NCT03227575 -
Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control
|
N/A | |
Completed |
NCT01870947 -
Assisted Exercise in Obese Endometrial Cancer Patients
|
N/A | |
Recruiting |
NCT06007404 -
Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
|
||
Recruiting |
NCT05972564 -
The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function
|
Phase 1/Phase 2 | |
Recruiting |
NCT05371496 -
Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction
|
Phase 2 |